slide 1

Back to the List of the Granted Patents                                                Click here to download AP2130 PDF

(11)    Patent No :    AP 2130    (73) Applicant(s)       
(21)    Application No :    AP/P/2007/003941    TIAN Shengxun, First Teaching Hospital, Resident No. 6       
            Building, Henan University of Traditional Chinese Medicine,       
(22)    Filing Date :    12.08.2005    450000, Henan,       
(24)            Peoples Republic of China       
    Date of Grant &    13.05.2010           
(45)    Publication :

(30)    Priority Data                    (72) Inventors   
    (33) Country    (31) Number    (32) Date    TIAN Shengxun, China   
    EP            04019119.9    12.08.2004           
    CN            200410091146.8 19.11.2004    (74) Representative   
(84)    Designated State                   
    BW    GM    GH    KE    LS    MW    MZ   NA   SL    FISHER CORMACK & BOTHA   
    SD    SZ    T Z    UG    ZM    ZW               
(51)    International    Classification    A61K 35/84 (2006.01)    A61K 9/16 (2006.01)   
                            A61K 9/20 (2006.01)       
(54)    Title

An antiviral pharmaceutical product and manufacture thereof

(57)    Abstract

The present invention relates to an antiviral combination and manufacture thereof. The combination comprises one or two or more formulations, and each of the formulations is made by using at least one of the following components as active ingredient. In addition, the combination is manufactured by using at least three of the following components as active ingredients, wherein the components are: Radix Isatidis, Radix Glycyrrhizae, Fructus Trichosanthis, Rhizoma Pinelliae, Rhizoma Zingiberis, Radix Astragali, Radix Salviae Miltiorrhizae, Honey-fried Radix Glycyrrhizae, Radix Trichosanthis, Radix Ginseng or Radix Panacis Quingquefolii, Radix Angelicae Sinensis and Cordyceps. The combination is useful for treatment of infections of virus, in particular retrovirus or hepatitis B virus and hepatitis C virus, especially for treatment of HIV infection, preferably for treatment of HIV/AIDS.

(56)  Documents Cited :    WO 2004 105701 A2


Join our newsletter for CIPIT news through subscriptions!


Social Media


Contact Us

TEL : (254) 703 034 612